VIDEO: ‘Reassuring’ data on long-term efficacy of dupilumab at CHEST 2022

In this Healio video exclusive, Nicola A. Hanania, MD, MS, discusses CHEST Annual Meeting presentations that focused on the role of dupilumab in asthma treatment.

Highlights of these presentations included data on the long-term safety and efficacy of dupilumab in adults and in children aged 6 years and older, according to Hanania, professor of medicine and director of the Airways Clinical Research Center at Baylor College of Medicine.

“[The] long-term TRAVERSE study, that looked at oral corticosteroid sparing, showed that over even 96 weeks dupilumab reduced oral steroids and improved and maintained clinical outcomes, reassuring us that the effect is not just short-lived but also long-term,” Hanania, who is also the clinical sciences representative for the Baylor College of Medicine Faculty Senate, told Healio.

References:

Bacharier LB. Assessment of the long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION Study). Presented at: CHEST Annual Meeting; Oct. 16-19, 2022; Nashville, Tennessee.

Gurnell M. Dupilumab treatment leads to sustained reductions in oral corticosteroid use in patients with oral-corticosteroid-dependent severe asthma. Presented at: CHEST Annual Meeting; Oct. 16-19, 2022; Nashville, Tennessee.

Lugogo NL. Characterization of asthma patients treated with dupilumab in a real-world setting: The RAPID registry. Presented at: CHEST Annual Meeting; Oct. 16-19, 2022; Nashville, Tennessee.

For more information:

Nicola A. Hanania, MD, MS, can be reached on Twitter: @Hananianick.